US 2026/0265200 A1Published application

Cancer treatments targeting cancer stem cells

AssigneeRemedy Plan, Inc.

InventorsYushma Bhurruth-Alcor, Gregory Thomas Crimmins, Dennise Alexandra De Jesús Diaz, Caroline Mae Robb

Life of this patent

Estimating the term…

Loading patent…

Abstract

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

Claims119

Dependent claims

A compound of Formula (0):

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
R1 is substituted or unsubstituted, C1-12 alkyl or substituted or unsubstituted, C1-12 heteroalkyl;
R2 is hydrogen, substituted or unsubstituted, C1-12 alkyl, substituted or unsubstituted, C1-12 heteroalkyl, substituted or unsubstituted, 3- to 13-membered heterocyclyl-C1-12-alkyl, substituted or unsubstituted, 3- to 13-membered carbocyclyl-C1-12-alkyl, or a nitrogen protecting group;
when R2 is unsubstituted methyl, R1 is not unsubstituted ethyl;
R3 is hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
each instance of Ra is independently hydrogen, substituted or unsubstituted, C1-6 alkyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom;
each instance of R4 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
each instance of R5 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
R6 is hydrogen, substituted or unsubstituted, C1-6 alkyl, or a nitrogen protecting group;
each instance of R8 is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
each instance of R9 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2, or two instances of R9 are joined to form a 3- to 13 membered heterocyclyl, 3- to 13 membered heterocyclyl, 6- to 12 membered aryl ring, or 5- to 14 membered heteroaryl ring;
n is an integer from 0 to 4, inclusive;
m is an integer from 0 to 3, inclusive;
p is an integer from 0 to 3, inclusive;
and
q is an integer selected from 0 and 1;
provided that the compound is not of the formula:

14 more elements

A compound of Formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
R1 is substituted or unsubstituted, C1-12 alkyl or substituted or unsubstituted, C1-12 heteroalkyl;
R2 is hydrogen, substituted or unsubstituted, C1-2 alkyl, substituted or unsubstituted, C1-12 heteroalkyl, substituted or unsubstituted, 3- to 13-membered heterocyclyl-C1-12-alkyl, substituted or unsubstituted, 3- to 13-membered carbocyclyl-C1-12-alkyl, or a nitrogen protecting group;
when R2 is unsubstituted methyl, R1 is not unsubstituted ethyl;
R3 is hydrogen, halogen, substituted or unsubstituted, C1-6alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
each instance of Ra is independently hydrogen, substituted or unsubstituted, C1-6 alkyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom;
each instance of R4 is independently hydrogen, halogen, substituted or unsubstituted, C1-6alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
each instance of R5 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
R6 is hydrogen, substituted or unsubstituted, C1-6alkyl, or a nitrogen protecting group;
each instance of R8 is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
each instance of R9 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, —ORa, —COORa, —CORa, —N(Ra)2, —CN, or —(C═O)N(Ra)2;
n is an integer from 0 to 4, inclusive;
m is an integer from 0 to 3, inclusive;
and
p is an integer from 0 to 3, inclusive;
provided that the compound is not of the formula:

13 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/563,451Filed 11 Mar 2026
Priority: 6 Nov 2019
Published: 10 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07D 213/82
Amides; Imides: in position 3
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/00
Antineoplastic agents
C07D 405/14
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having…:…

Family

Application62/931,531Us provisional application · filed 6 Nov 2019
Application17/774,583Continuation · filed 6 Nov 2020
Application19/563,451Continuation
US 12,612,368 B2Related patent
US 2023/0023124 A1Published application
US 2026/0265200 A1This patent

From the US filing history. Foreign family members aren’t listed.